Date published: 2026-9-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

IFN-α7 CRISPR/Cas9 KO Plasmid (m): sc-421044

0.0(0)
Write a reviewAsk a question
Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • IFN-α7 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IFN-α7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    IFN-α7 CRISPR/Cas9 KO Plasmid (m)

    sc-421044
    20 µg
    $397.00

    Overview

    Ifna7 encodes mouse interferon-α7 (IFN-α7), a type I interferon cytokine produced primarily in response to viral and nucleic acid sensing signals. IFN-α7 engages the IFNAR receptor complex to activate JAK1/TYK2-dependent phosphorylation of STAT1/STAT2, promoting formation of the ISGF3 transcriptional complex and induction of interferon-stimulated genes that shape innate and adaptive immunity. This signaling axis intersects with pattern-recognition receptor pathways including TLR and RIG-I-like receptors, influencing antigen presentation, cytokine networks, and antiviral restriction programs. Dysregulated type I interferon activity is implicated in inflammatory and autoimmune phenotypes as well as tumor-immune interactions, making Ifna7 a useful node for mechanistic studies of interferon-driven biology.

    IFN-α7 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ifna7 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ifna7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ifna7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IFN-α7 protein expression.

    This CRISPR knockout system enables efficient generation of Ifna7-deficient cell models for investigation of IFN-α7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Ifna7 exon(s) critical for IFN-α7 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Ifna7 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by IFN-α7 CRISPR/Cas9 KO Plasmid (m) and IFN-α7 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ifna7 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by IFN-α7 HDR Plasmid (m) and IFN-α7 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ifna7 homology arms to support homology-directed repair at defined Ifna7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.